As of September 17, 2020

Internal Selection Competitions

Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS=CoV-2 (WUSTL Key required)
Internal Selection deadline is 8/20/2020 (STILL OPEN); Applications due to NIH 09/18/2020

  • The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
  • Specifically, this FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Emergency Awards: RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (WUSTL Key required)
Internal Selection deadline is 08/20/2020 (STILL OPEN); Applications due to NIH 09/18/2020

  • The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
  • Specifically, this FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. These sensing devices must be able to associate VOC patterns to patients with symptomatic and asymptomatic COVID-19. These devices are expected to actively detect VOCs from skin and oral cavities of COVID-19 patients, without being invasive, or affecting the integrity of the skin and oral cavity. For VOC monitoring, these sensing devices can be Electronic-nose (E-nose) technology or Gas Chromatography (GC). Therefore, this program is called SCENT, which stands for Screening for COVID-19 by Electronic-Nose Technology. This FOA seeks to advance novel biosensing technologies that are innovative, safe, and effective using integrated artificial intelligent, pattern recognition and machine learning systems that would make it possible for the detection, diagnosis, prediction, and monitoring of COVID-19 in clinical, community and everyday settings.
  • This FOA requires multidisciplinary collaborations to ensure project success. Disciplines may include: biomedical engineers, material scientists, biosensing experts, software engineers, chemists, dentists, clinicians, virologists, clinical trialists, biostatisticians, data analysts and/or other relevant experts in academia and industry. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020

Internal Opportunities

The Institute for Informatics (I2) and the Healthcare Innovation Lab are sponsoring a “spin-off” Big Ideas Grant Program
Applications due 09/30/2020; Grant winners notified 10/19/2020

  • This grant provides an opportunity for teams to secure funding for COVID-19-related informatics and care delivery innovations. Applicants may request up to $50,000. Supports novel and innovative projects that are clinically relevant, technically feasible, and operational sustainable.
  • Teams must be co-led by a BJC employee and a WUSM faculty member. Project teams should consist of members with relevant clinical, investigative and operational skills. WUSM/BJC collaboration is required.
  • Big Ideas COVID info Sheet
  • Big Ideas COVID flyer

Opportunities for Current NIH Funded Researchers (Competitive Revisions & Supplements)

See examples of NIH Administrative Supplements in Box (WUSTL Key required)

*NEW* Limited Competition Emergency Awards: Shared Personal Protective Equipment Resources for COVID-19 Related Vaccine and Treatment Clinical Trials and Clinical Studies (S10 Clinical Trial Not Allowed) (PAR-20-256)

  • The purpose of this public health emergency funding opportunity is to provide Personal Protective Equipment (PPE) to directly support the needs of the NIAID’s vaccine and treatment clinical trials and clinical studies for COVID-19. This program will ensure that adequate protective equipment is available to directly assist in safely carrying out the clinical activities and direct interactions with the patients participating in the trial. Eligibility is limited to recipients conducting COVID-related clinical research and clinical studies supported by NIAID’s emergency appropriation provided by “The Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020” and “The Coronavirus Aid, Relief and Economic Security (CARES) Act”.
  • Applications accepted on a rolling basis.
  • NIAID intends to commit up to $25M for this initiative. Application budgets are not limited but need to reflect the actual needs of the proposed project.

Notice of Special Interest (NOSI): Simulation Modeling and Systems Science to Address Health Disparities (NOT-MD-20-025)
Expiration date is 5/8/2023; First available due date is 10/05/2020

  • Research Objectives:
    • Foster trans-disciplinary partnerships and collaborations in understanding the etiology and causal pathways of health disparities using SMSS
    • Use SMSS to identify modifiable barriers and cost-effective factors to reduce and eventually eliminate health disparities
    • Use SMSS to improve patient safety and reduce medical errors for populations affected by health disparities
    • Use SMSS to assess and predict the spread and consequences of pandemics (e.g., SARS-CoV-2) and the effectiveness of interventions in populations affected by health disparities
    • Provide evidence-based simulation or prediction of the impact of effective or ineffective health disparities interventions delivered in real-world settings
    • Promote big data harmonization and novel analytic methods in SMSS to address minority health and health disparities
  • Research Methodology
    • Examples of research methods could include but are not limited to:
    • System dynamics modeling
    • Network Analysis
    • Agent-based modeling
    • Dynamic microsimulation modeling
    • Discrete event simulation
    • Markov modeling
    • Hybrid simulation modeling (e.g., sequential design, enrichment design, integration design, and parallel design)
  • Research Topics: Applications should be relevant to the objectives of the funding opportunity announcement and to at least one of the participating institutes’ and offices’ research interests. Researchers are strongly encouraged to review the general research interests of the participating ICs.

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool (NOT-OD-20-152)
Due date is September 1, 2020

  • NIH is issuing this NOSI in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency NOSI from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. The goal of the RADx-rad initiative is to encourage the development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus or other markers of the COVID-19 disease that can be used in future outbreaks of COVID-19 and that could be applicable to other, as yet unknown, viruses. Specifically, the goal of this NOSI is to solicit proposals to enhance the utility of chemosensory testing as a COVID-19 screening tool by using objective tests to examine the onset and prognostic value of chemosensory loss and to encourage the development and/or deployment of home-based and on-site chemosensory tests. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Select Research Activities related to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-059)
Notice expires on 7/2/21

  • NIAID is allowing the submission of applications for Competitive Revisions to active grants to increase and enhance select research efforts to facilitate the Federal SARS-CoV-2/COVID-19 research response. Areas of interest are limited to:
    • Support to BSL3 facilities actively engaged in the SARS-CoV-2/COVID-19 research response, e.g., equipment sharing arrangements. Applications proposing new construction, alterations and renovations for planned and active BSL3 facilities are not responsive to this NOSI;
    • Generation of critical reagents to support the SARS-CoV-2/COVID-19 research response;
    • Expansion of relevant data systems to expeditiously share SARS-CoV-2/COVID-19 research resources with the broad research community; and
    • Expansion of clinical trial infrastructure, or site preparation, for urgent SARS-CoV-2/COVID-19 clinical trial activities. Applications proposing clinical trials are not responsive to this NOSI.

Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions and Administrative Supplements for Research on Coronavirus Disease 2019 (COVID-19) in Individuals with Down Syndrome for the INCLUDE Project
Application Due Dates are 11/12/20, 3/12/21, or 7/12/21

  • This NOSI highlights the urgent need for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) in individuals with Down syndrome in conjunction with the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project. The overarching goal of this NOSI is to improve understanding and treatment of COVID-19 infection in individuals with Down syndrome and reduce COVID-19 associated morbidity and mortality for this population, which may be disproportionately affected by, have higher infection rates of, and/or be at elevated risk for adverse outcomes from contracting the virus.

Notice of Special Interest (NOSI): Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19
Applications will be accepted on a rolling basis from June 10, 2020 through December 15, 2020. Applications submitted before July 15, 2020 will be considered for funding in in Fiscal Year 2020

  • The purpose of this NOSI is to support research to address secondary health effects of the social, behavioral, and economic changes, particularly among populations who experience health disparities and vulnerable populations through the use of digital health assessments and interventions to yield measurable near-term impact. Administrative supplements and competitive revisions applications are expected to describe how research outcomes will lead to a tangible difference within 6 months to a year of completing the supplement work, with respect to improving how we identify, treat, or provide services for health conditions secondary to the COVID-19 pandemic for health disparate and vulnerable populations. 

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements for Coronavirus Disease 2019 (COVID-19) Research within the Mission of NIDCR (NOT-DE-20-022)
Application due date: November 2, 2020

  • NIDCR will place a high priority on topics that would be of immediate and high impact to protect and ensure the safety of personnel and patients in dental practices.  New knowledge about SARS-CoV-2 transmissibility, stability on surfaces, viral particle size, and presence in saliva have catalyzed a need to consider how the practice of dentistry will be performed in the near and long-term future.

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions on Coronavirus Disease 2019 (COVID-19) for Currently Active NHLBI Phase I-III Clinical Trials (NOT-HL-20-782)
Expires 10/6/20

  • NHLBI seeks to leverage existing clinical trials expertise and, using NHLBI programs that are actively conducting Phase I-III clinical trials, to rapidly initiate and conduct Phase I-Phase I/II (bridging) clinical trials in patients at risk for SARS-CoV-2 infection and/or patients with COVID-19. It is strongly recommended that the parent activity code be one of the following: P01, R01, R33, R41, R42, R43, R44, U01, U24, U54, UH3, or UM1.

Notice of Special Interest (NOSI): Availability of Urgent Competitive Revisions and Administrative Supplements For Research on Biological Effects of the 2019 Novel Coronavirus on the Nervous System
(NOT-NS-20-051)

Expires 4/15/21

  • NINDS is encouraging the submission of competitive revision or administrative supplement applications for supplements to address the biology, pathophysiology, prevention, diagnosis, sequelae, or treatment of the 2019 Novel Coronavirus that are directly related to the NINDS mission.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus and the Behavioral and Social Sciences (NOT-OD-20-097)
Applications will be accepted on a rolling basis through 3/31/21

  • OBSSR, NHLBI, NIA, NIAAA, NIDDK, NIEHS, NCCIH, NCI, and ORWH encourage submission of applications for urgent competitive revisions or administrative supplements to active grants studying existing longitudinal cohorts, particularly those cohorts with considerable data relevant to COVID-19 social and behavioral factors prior and subsequent to the SAR-CoV-2 outbreak in various locations. Submissions are encouraged to consider four areas: public health mitigation efforts; economic, social and personnel well-being; misinformation being communicated; downstream health effects from economic and social impacts.

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Mental Health Research on the 2019 Novel Coronavirus (NOT-MH-20-047)
Applications accepted on a rolling basis until 4/15/21

  • NIMH, NIA, NIAAA, and NIMHD are accepting applications for supplements and revisions to active projects that significantly improve our understanding of the risks, mechanisms, and treatment in response to COVID-19 among individuals at risk for, or experiencing mental disorders across the full lifespan. This includes but is not limited to, individuals with Mild Cognitive Impairment (MCI), Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD) and their healthcare providers and caregivers.

Notice of Special Interest (NOSI): Competitive and Administrative Supplements for the Impact of COVID-19 Outbreak on Minority Health and Health Disparities (NOT-MD-20-019)
Applications accepted on a rolling basis until 5/1/21

  • NIMH, NIA, and NIMHD are accepting applications for supplements and revisions to active projects. This NOSI is soliciting research in health disparity populations that -seeks to understand: 1) how state and local policies and initiatives mitigate or exacerbate disparities in health services use and health outcomes; 2) the role that community-level protective and resilience factors and interventions have in mitigating the effects of the sector disruptions that the COVID-19 outbreak causes; and 3) how behavioral and/or biological mechanisms may contribute to COVID-19 manifestations.

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Urgent Competitive Revisions for Research on Stress Management in Relation to Coronavirus Disease 2019 (COVID-19) (NOT-AT-20-011)
Applications accepted on a rolling basis through 10/6/20

  • NCCIH, NIA, and NIAAA are accepting applications for supplements and revisions to active projects. Topics of specific interest for this NOSI include research on stress management strategies, including mind and body approaches,that individuals may engage in remotely to address stressors related to social distancing, as well as to address recovery and recurrence of symptoms during and after COVID-19 infections.

Notice of Special Interest (NOSI): NIEHS Support for Understanding the Impact of Environmental Exposures on Coronavirus Disease 2019 (COVID-19) (NOT-ES-20-015 / PA-20-135)
Applications are accepted the first week of each month. See Notice for specific dates. (Notice expires on 5/4/21)

  • NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. NIEHS is accepting applications addressing COVID-19 through the urgent competitive revision, and time-sensitive mechanisms (see Application Information below).

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-008)
Applications accepted on a rolling basis through 11/10/20

  • The NIBIB is seeking applications from current grantees to develop life-saving technologies that can be ready for commercialization within one to two years.

Notice of Special Interest (NOSI): NIA Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) (NOT-AG-20-022)
Applications will be accepted on a rolling basis from April 6, 2020 through May 1, 2021

  • In order to rapidly improve our understanding and available control measures for 2019-nCoV, NIA is encouraging the submission of applications for either Administrative Supplements (PA-18-591) or Competitive Revisions (PA-18-935) to active grants to address multiple areas of interest within the mission of NIA.

NIDA Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (NOT-DA-20-047)
Applications will be accepted on a rolling basis through 3/31/21

  • NIDA is especially interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders. Applications must be submitted using the following funding opportunities: PA-18-935, which is intended to provide funds for NIH grantees applying to expand the scope of their active grant, or PA-18-591, which is intended to provide funds for NIH grantees where the work proposed in the supplement is fully within the scope of the ongoing grant.

NIGMS Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 (NOT-GM-20-025)
Applications will be accepted on a rolling basis until 2/5/21

  • NIGMS will accept the submission of applications to address incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants), repurpose/modify diagnostics tools for rapid detection (SBIR/STTR only) and development of therapeutics (SBIR/STTR only).  Applications must be submitted to PA-18-935 which is intended to provide funds for NIH grantees applying to expand the scope of their active grant.

NIAID Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-031)
Application due dates depend on grant mechanism (Notice expires on 4/5/21)

  • National Institute of Allergy and Infectious Diseases (NIAID) is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. Applications may be submitted as administrative supplements (PA-18-591) to existing awards.

Clinical and Translational Science Awards Limited Funding Opportunities

Notice of Special Interest (NOSI): New Administrative Supplement Applications to UL1 and U24 CTSA Awards to Address COVID-19 Public Heath Need
Applications will be accepted immediately and on a rolling basis through November 10, 2020

  • Encouraging supplement proposals to support the NCATS National COVID Cohort Collaborative (N3C): Provision of clinical data in specified formats to support illness/infection status/surveillance determinations and/or clinical study data (awards anticipated to be $50,000 to $100,000 Total Costs)

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions and Administrative Supplements to Clinical and Translational Science Award (CTSA) Program Awards to Address 2019 Novel Coronavirus Disease (COVID-19) Public Health Needs
Applications will be accepted immediately and on a rolling basis through November 10, 2020

Notice of Special Interest (NOSI): Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need
Application due dates depend on grant mechanisms

NIH Funding Opportunities (New Applications)

Notice of Special Interest: Emerging Viral Infections and their Impact on the Male and Female Reproductive Tract (NOT-HD-20-021)
Expiration date is 07/16/2023; First Available due date is 10/05/2020.

  • The purpose of this Notice is to invite applications proposing cutting-edge research on emerging viral infections that are thought to primarily impact non-reproductive sites, at least at initial presentation, but may also affect the male and/or female reproductive tract. The recent global outbreak of the novel coronavirus, SARS-CoV-2, is not an anomaly and will most likely not be the last virus occurrence. Today, infectious diseases are emerging and reemerging more quickly than ever before. In the last four-five years alone, two viral infections, one caused by the Zika virus (ZIKV) and the other caused by a SARS-CoV-2 (Covid19), have spread world-wide, resulting in death, severe disease with yet, unknown, long-term morbidities., or severe birth defects to the new-born. Both ZIKV and SARS-CoV-2 infections may affect male and/or female reproductive systems in addition to other non-reproductive sites. Therefore, it becomes essential to investigate possible effects of emerging viruses on reproductive tissues and cells to better understand potential impacts on fertility that may be sex specific.
  • Currently, knowledge gaps exist in our understanding of viral infections of both male and female reproductive tract tissues. This NOSI is interested in the recently emergent ZIKA and novel corona viruses, as well as other yet unidentified viruses which may significantly impact public health. Areas of interest of this NOSI include, but are not limited to:
    • Consequences of infection, e.g., cells affected and outcomes of infection – infertility, miscarriage, live births, orchitis, epididymitis, pelvic pain;
    • Mechanism of action for infectivity of reproductive tract tissues;
    • Mechanism of sexual transmission;
    • Whether the reproductive tract acts as a reservoir for viruses;
    • Sex-specific differences in infection as they may relate to reproductive tract tissues and cells;
    • The impact of race and ethnicity on reproductive system impacts of viruses;
    • Impact of nutrition, e.g., Vitamin D sufficiency and the understanding of mechanisms that explain the impact of obesity;
    • Development of model systems to study infections in reproductive tract tissues, e.g., organoids (for R21 applications only)
  • Non-responsive applications:
    • Infections exclusively localized to the reproductive tract, e.g., urinary tract infections, chlamydia, HPV, HSV, hepatitis B;
    • Epidemiological analysis of a particular infection.

Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2
Expiration date is 9/1/2021; First Available due date is 9/01/2020

  • This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate:
    • SARS-CoV-2 candidate vaccines
    • non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19
    • therapeutic approaches to treat COVID-19
  • Please note, studies evaluating behavioral interventions (e.g., impact of face masks, hand- washing, social distancing) and those focused on disinfecting surfaces and equipment are not responsive and will not be considered for this NOSI initiative.
  • Investigators interested in responding to this NOSI are strongly encouraged to submit a written request for prior consultation to the email address listed below prior to submission of an NIAID Clinical Trial Implementation (U01) Cooperative Agreement application in response to PAR-18-633 to discuss the proposed project in the context of the needs identified above. This request should be as succinct as possible and include the study title and a brief description of the study and product to be evaluated; study PI; primary institution and potential collaborating sites; industry partners, if applicable; and a cost estimate. As a reminder, per NIH policy, applicants requesting $500,000 or more in direct costs in any year (excluding consortium F&A) must contact NIAID staff listed below no later than 6 weeks before submission and follow the Policy on the Acceptance for Review of Unsolicited Applications that Request $500,000 or More in Direct Costs as described in the SF424 (R&R) Application Guide.

Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) (PAR-20-238)
Application due dates: May 17, 2021, May 17, 2022, May 17, 2023

  • The purpose of this funding opportunity announcement (FOA) is to support research on interventions to improve health in Native American (NA) populations. This includes 1) etiologic research, where there is a significant gap in knowledge, that will directly inform intervention development or adaptations, 2) research that develops, adapts, or tests the efficacy or effectiveness of health promotion and disease prevention interventions, 3) research that tests culturally informed treatment or recovery interventions and 4) where a sufficient body of knowledge on intervention efficacy exists, research on dissemination and implementation that develops and tests strategies to overcome barriers to the adoption, integration, scale-up, and sustainability of effective interventions. Existing data suggest that significant acute and chronic disease inequities exist for NA populations.  Concurrently, NA populations experience unique sociopolitical, historical, and environmental stressors and risks that may exacerbate health conditions and/or impact the effectiveness of existing solutions to address the conditions. They also possess unique strengths and resiliencies that can mitigate stressors or inform intervention strategies. Through this initiative, intervention and related research is sought to build upon community knowledge, resources, and resilience to test science-based, culturally appropriate solutions to reduce morbidity and mortality through identification and remediation of precursors to diseases and disorders and through culturally informed treatment.  Interventions should be designed with a consideration for sustainability within the communities where they are tested, and have the flexibility to be readily adapted, disseminated, and scaled up to other communities where culturally appropriate. For the purposes of this FOA, Native Americans include the following populations: Alaska Natives, American Indians (whose ancestral lands fall at least partially within the U.S. mainland border), and Native Hawaiians.  The term ‘Native Hawaiian’ means any individual any of whose ancestors were natives, prior to 1778, of the area which now comprises the State of Hawaii.
  • NHLBI: One of the Examples of projects of interest to NHLBI include the following: Strategies and behavioral interventions that may mitigate the impact of COVID-19 on heart, lung, blood, and sleep diseases and disorders

Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS=CoV-2 (WUSTL Key required)
Internal Selection deadline is 8/20/2020 (STILL OPEN); Applications due to NIH 09/18/2020

  • The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
  • Specifically, this FOA seeks to use developed technologies for single vesicle or exosome isolation and analysis and reposition these technologies for the detection of SARS-CoV-2. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Emergency Awards: RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (WUSTL Key required)
Internal Selection deadline is 08/20/2020 (STILL OPEN); Applications due to NIH 09/18/2020

  • The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
  • Specifically, this FOA is seeking applications for a portable sensing device to detect volatile organic compounds (VOCs, i.e., scents or odors) emanating from skin or exhaled breath, saliva and different oral tissues from the oral cavity. These sensing devices must be able to associate VOC patterns to patients with symptomatic and asymptomatic COVID-19. These devices are expected to actively detect VOCs from skin and oral cavities of COVID-19 patients, without being invasive, or affecting the integrity of the skin and oral cavity. For VOC monitoring, these sensing devices can be Electronic-nose (E-nose) technology or Gas Chromatography (GC). Therefore, this program is called SCENT, which stands for Screening for COVID-19 by Electronic-Nose Technology. This FOA seeks to advance novel biosensing technologies that are innovative, safe, and effective using integrated artificial intelligent, pattern recognition and machine learning systems that would make it possible for the detection, diagnosis, prediction, and monitoring of COVID-19 in clinical, community and everyday settings.
  • This FOA requires multidisciplinary collaborations to ensure project success. Disciplines may include: biomedical engineers, material scientists, biosensing experts, software engineers, chemists, dentists, clinicians, virologists, clinical trialists, biostatisticians, data analysts and/or other relevant experts in academia and industry. The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020

Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kids) (R61/R33 Clinical Trial Optional) RFA-OD-20-023
Applications due September 30, 2020

  • The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
  • This FOA seeks to support innovative research to develop novel, new or unique and non-traditional approaches (e.g. diagnostic and prognostic biomarkers and/or biosignatures) to identify and characterize the spectrum of SARS CoV-2 associated illness, including the multisystem inflammatory syndrome in children (MIS-C) and, through a prognostic algorithm, predict the longitudinal risk of disease severity after a child is exposed to and may be infected with SARS-CoV-2 to properly tailor his or her management and optimize health outcomes.
  • The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)
LOI due date is 8/30/2020; Applications due 9/30/2020

  • NIH is issuing this Funding Opportunity Announcement (FOA) in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
  • This FOA invites applications to pursue development and validation studies of COVID-19 surveillance methods, not based or focused on direct viral testing of individuals, in settings and institutions, including residential, with a high density of individuals who are together for prolonged periods of time. There are numerous promising technologies which could allow for multimodal surveillance inputs. However, these technologies are often not interoperable, not optimized for integration to increase robustness and not tested for general applicability to public health or for the specific need of high-risk population surveillance. Applications are invited that translate a combination of digital surveillance modalities into platforms that can assist the professional staff of high-risk facilities in making clinically meaningful care recommendations for patients at risk of COVID-19 or other respiratory viruses. Projects proposed may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate.
  • The funding for this initiative is provided form the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed. (RFA-OD-20-014)
LOI due date is 8/21/2020; Application due date is 9/15/2020

  • The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS),for 2019 Novel Coronavirus (COVID-19). This emergency FOA from the National Institutes of Health (NIH) provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
  • This RFA will support the early stage development of an innovative platform that integrates biosensing with touchscreen or other digital devices to achieve detection and tracing of SARS-CoV-2 in real-time. Projects are expected to demonstrate proof-of-concept of SARS-CoV-2 detection with high sensitivity and specificity, sensor functionality, and automatic detection by touchscreen or other digital devices. To achieve the goal of this FOA, the proposed project needs to be milestone driven and carried out by a multidisciplinary team with complementary expertise.
  • The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed) RFA-OD-20-021
Applications due date is 9/18/2020

  • The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative.
  • The goal of this RFA is to solicit Fast-Track STTR applications to advance development of novel, non-traditional, safe and effective biosensing and detection approaches to identify the current SARS-CoV-2 virus or other biomarkers of the COVID-19 disease for use in outbreaks of COVID-19, as well as for use in future pandemics resulting from unknown viruses.
  • The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed) RFA-OD-20-019
Applications due 9/30/2020; LOI due 8/31/2020

  • NIH is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. Specifically, this FOA seeks to fund a single cooperative agreement for a Data Coordination Center (DCC) to serve as a communication center and data hub for RADx-rad awardees. The funding for this award is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19)(U01 – Clinical Trials Not Allowed) RFA-OD-20-015
Applications due 09/15/2020

  • The National Institutes of Health (NIH) is issuing this funding opportunity announcement (FOA) in response to the declared public health emergency issued by the Secretary, Department of Health and Human Services (DHHS), for the 2019 Novel Coronavirus (COVID-19). This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. As one of the programs within the NIH Rapid Acceleration of Diagnostics-Radical (RADx-rad) program the RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) FOA will support wastewater-based testing (WBT) surveillance which can provide detailed mapping of the extent and spread of COVID-19. Wastewater testing has been shown to be orders of magnitude cheaper and faster than clinical screening, albeit serving as a complementary approach rather than substituting individual-level testing and screening. The purpose of this FOA is to solicit cooperative agreements both for field studies and for small business research and development projects in the field of WBT, to address topics such as: investigation and demonstration of specific approaches aiming to increase sensitivity and to inform and optimize sample collection; implementation and development of optimized approaches to extrapolate estimation of population-level data within the community; development of optimized intervention strategies, and incorporation of computational, statistical, and mathematical models.
  • The funding for this initiative is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

Notice of Special Interest (NOSI): Comprehensive Care for Adults with Type 2 Diabetes Mellitus from Health Disparity Populations (NOT-MD-20-026)
First Available Due date 10/5/20; Notice expires on 5/8/21

  • The purpose of this Notice of Special Interest is to support multidisciplinary, investigative and collaborative research focused on developing and testing multi-level strategies to effectively implement recommended guidelines of comprehensive clinical care for individuals with Type 2 diabetes from health disparity populations.
    • One example of potential topic areas mentions COVID-19
      • Studies on the multi-level effects of the COVID-19 pandemic and/or their intersection on access to health care services and continuity of care, for example patient level factors (e.g., loss of health insurance due to job loss; impact on self-management due to caregiving and homeschooling responsibilities) health care setting level factors (e.g., changes and rescheduling of services due to policies on physical distancing; medication availability and refills, health care settings strategies and best practices to ensure appropriate and timely care), and societal factors (impact of policies on physical distancing on nutrition, physical activity, and emotional well-being). Costs/economic analyses are of interest.

Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01)
Applications will be accepted on a rolling basis, beginning on 8/6/2020

  • The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

Notice of Intent to Publish a Funding Opportunity Announcement for HEALthy Brain and Child Development Study (NOT-DA-20-069)

  • NIH plans to publish a set of Funding Opportunity Announcements (FOAs) as part of the Helping to End Addiction Long-termSM (HEAL) Initiative to support research project sites, a Data Coordinating Center, and a Consortium Administrative Core for the HEALthy Brain and Child Development (HBCD) Study. The primary objective of the HBCD Project is to conduct a large scale multi-site longitudinal study that can prospectively examine human brain, cognitive, behavioral, social, and emotional development beginning at birth and extending through middle childhood. The FOAs are expected to be published in Fall 2020 with an expected application due date in WINTER 2021.

Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional, RFA-DK-20-021)
Applications are due 12/16/20

  • This FOA support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. 

Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 – Clinical Trial Optional)
Applications are due 12/2/20, or 3/2/21

  • Focuses on the role and impact of digital health interventions [e.g., mobile health (mhealth), telemedicine and telehealth, health information technology (IT), and wearable devices] to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects (e.g., behavioral health or self-management of chronic conditions) that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations

Notice of Special Interest (NOSI): Utilizing Telemedicine or Other Remote-Based Platforms to Develop and Support Treatments for Substance Use Disorders
This notice applies to standard R01 and R21 due dates on or after October 5, 2020 and subsequent due dates until 1/8/24.

  • We expect this NOSI to accelerate the development of 1) remotely-delivered SUD treatment interventions, and 2) remote methods for collecting outcome measures evaluating the safety or efficacy of SUD treatments. These advances will facilitate the delivery of effective treatments to those in need and permit the execution of clinical trials when physical access to clinical research sites is limited. Ultimately, both these advances will lead to improved treatment options for individuals with SUD.

NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)
Applications are due: 10/1/20, 11/2/2020, 11/2/,2020, 12/1/2020, 1/4/2021, 2/1/2021

  • Invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19)

Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01- Clinical Trial Optional)
Applications are due: 12/1/20

  • Encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups


NIA Multi-site COVID-19 Related Clinical Trial Implementation Grant on Aging-Related Topics in at-risk Older Adult Populations (R01 Clinical Trial Required)
Applications are due October 1, 2020; November 2, 2020; December 1, 2020; January 4, 2021; and February 1, 2021.

  • This Funding Opportunity Announcement (FOA) invites applications for implementation of investigator-initiated multi-site clinical trials (all phases or stages) of interventions focused on specific aging-related issues to reducing transmission, risk, morbidity, mortality, severity, or complications of Coronavirus Disease 2019 (COVID-19). 

Notice of Special Interest (NOSI): NIDCD is Interested in Supporting Research on the Impact of COVID-19 on Mission Specific Sensory and Communication Disorders
This notice applies to due dates on or after October 5, 2020 and subsequent receipt dates through September 8, 2022.

  • NIDCD invites applications for research on COVID-19 in relation to NIDCD’s scientific programs of hearing, balance, taste, smell, voice, speech and language (HBTSVSL). Given the early stage of COVID-19 research, it is critical that there is a strong premise for research proposals submitted in response to this NOSI. When appropriate, NIDCD encourages multi-disciplinary approaches to move the research beyond in vitro and animal models.

RFA-AA-20-009 — Alcohol-HIV/AIDS Program Project Comorbidities, Coinfections, and Complications Research: Intervention and Cross-Cutting Foundational Research (P01 Clinical Trial Optional) 
Applications are due 11/17/20

  • The Funding Opportunity Announcement will solicit applications for human studies that will advance operations or implementation research in the context of alcohol and HIV/AIDS by facilitating the development of: (1) broader systems approaches for monitoring complex HIV and alcohol-related morbidity and mortality, and (2) interventions to reduce the impact of alcohol on HIV disease progression and transmission.  

NIH Director’s Emergency Transformative Research Awards (RFA-RM-20-020)
Applications due 9/30/20

  • Transformative Research Awards from CARES Act funding that bring new, innovative perspectives and approaches to the prevention of, preparation for, or response to coronavirus SARS-CoV-2, domestically or internationally. Any relevant area of coronavirus SARS-CoV-2 research is welcome, including behavioral/social science research, research on health disparities, novel therapeutics, and other related topics

New COVID-19 priority areas and due dates for PAR-19-373 and PAR-19-384, “Research on Biopsychosocial Factors of Social Connectedness and Isolation on Health, Wellbeing, Illness, and Recovery (R01)”
Next application due date: 3/17/21

  • These FOAs solicits research projects that seek to model the underlying mechanisms, processes, and trajectories of social relationships and how these factors affect outcomes in health, illness, recovery, and overall wellbeing. There are new priority topics related to COVID-19 pandemic.

RadX – Tech – NIH POCTRN Fast-Track Program for COVID-19 Test Development and Distribution Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing
Accepting proposals for support on a rolling basis until further notice

  • NIBIB is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities.

Notice of Special Interest (NOSI): Data Driven Research on Coronavirus Disease 2019 (COVID-19) (R21)(NOT-LM-20-011)
National Library of Medicine

  • NLM is accepted new R21 applications on the June 16, 2020 deadline only. NLM is encouraging the submission of R21 applications to address the following research areas of interest: (1) Methods for mining clinical data that can be used to identify or predict presence of COVID-19 in biomedical phenotype data, or other relevant topics such as discovery of risks for infection by SARS-Cov-2 viruses, use of standard terminologies for these viruses in federated health data sets; (2) Public health surveillance methods that mines genomic, viromic, health data, environmental data and/or data from other pertinent sources such as social media, to identify spread and impact of SARS-Cov-2

Long-Term Effects of Disasters on Health Care Systems Serving Health Disparity Populations (R01- Clinical Trial Optional) (PA-20-172)
Standard due dates starting 10/5/20

  • This FOA supports investigative and collaborative research focused on understanding the long-term effects of natural and/or human-made disasters, such as the COVID-19 pandemic, on health care systems serving health disparity populations in communities in the U.S.

Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed) (RFA-ES-19-011 / NOT-ES-20-015)
Applications are accepted the first week of each month. See Notice for specific dates. (Notice expires on 5/4/21)

  • NIEHS is particularly interested in applications that will provide insight into the role of environmental exposures in pathogenicity, transmission, individual susceptibility, or prevention and intervention strategies. NIEHS is accepting applications addressing COVID-19 through the urgent competitive revision, and time-sensitive mechanisms (see Application Information below).

Notice of Special Interest (NOSI): Availability of Emergency Competitive Revision and Administrative Supplements on Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-007)
Application standard due dates apply (Notice expires on 3/31/21)

  • The NIBIB is seeking new R01, R21, and R03 applications to develop life-saving technologies that can be ready for commercialization within one to two years.

Notice of Special Interest (NOSI): Small Business Research and Development of Biomedical Technologies for Coronavirus Disease 2019 (COVID-19) (NOT-EB-20-006)
Standard application due dates apply (Notice expires on 3/31/21)

NIAID Notice of Special Interest (NOSI): Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-AI-20-031)
Application due dates depend on grant mechanism (Notice expires on 4/5/21)

  • National Institute of Allergy and Infectious Diseases (NIAID) is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19. Applications may be submitted through R03, R21, or R01 mechanisms.

NCATS Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19) (NOT-TR-20-012)
Application due dates vary by mechanism (Notice expires on 10/17/20)

  • National Center for Advancing Translational Sciences (NCATS) is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.  Grant mechanisms include Bench Testing (UG3/UH3), Clinical Trial Planning (U34), or Clinic Testing (U01).

NSF Funding Opportunities & Priorities

NSF Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19  (Funding Opportunity Number: NSF 20-065)
There are four submission windows for Phase I proposals in 2020.

  • The Division of Innovation and Industrial Partnerships (IIP) of the Engineering Directorate invites US-based small businesses to submit Phase I proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis

Joint NSF-BSF Programs Dealing with the Coronavirus Disease
Applications may be submitted anytime

  • The U.S.-Israel Binational Science Foundation (BSF) is accepting applications dealing with the Coronavirus Disease in all the active NSF-BSF programs. Applications must be written jointly by an Israeli scientist in an Israeli institution and a U.S. scientist from a U.S. research institution. Proposals should be submitted through the NSF Rapid Response Research (RAPID) funding mechanism. Presently, all biology units of the NSF (BIO), Geosciences, Materials, Physics and CBET divisions are open for submission.

NSF Dear Colleague Letter on the Coronavirus Disease 2019 (COVID-19) (NSF 20-052)
Applications may be submitted anytime

  • NSF is accepting proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

NSF Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19) (NSF 20-055)
Applications may be submitted anytime

  • The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

Department of Energy/Private Sector

COVID-19 High Performance Computing (HPC) Consortium Request for Proposals
Applications may be submitted anytime

  • The COVID-19 High Performance Computing Consortium is a unique private-public effort to bring together federal government, industry, and academic leaders who are volunteering free compute time and resources on their world-class machines. Researchers are invited to submit COVID-19 related research proposals to the consortium, which will then be reviewed for matching with computing resources from one of the partner institutions.

NIST

NIST Manufacturing USA National Emergency Assistance Program (2020-NIST-MFGUSA-NEAP-01)
Applications will be accepted on rolling basis
(Washington University is not eligible as the lead institution but may participate on an application.)

  • National Institute of Standards and Technology (NIST) invites Manufacturing USA institutes to propose high-impact projects designed to respond to the COVID-19 pandemic.  Projects may include medical countermeasures; non-medical countermeasures; leveraging institute capabilities to strengthen state and community resilience; grants to companies and technical support to accelerate productions of critical materials, equipment, and supplies; creation of additional production facilities; technology roadmapping for pandemic response and recovery; reshoring the manufacture of critical conventional drugs and ensuring supply chain for critical materials related to pandemic response; or workforce development and training for a skilled advanced manufacturing workforce.

USAID

COVID-19 FUNDING REQUESTS AND UNSOLICITED PROPOSALS
Concepts accepted on a rolling basis

  • USAID is responding to the COVID-19 pandemic with decisive action at home and abroad. Our priorities in the COVID-19 response are to protect the safety and health security of our global workforce, ensure that we can continue our life-saving mission across the world, and support partner countries in their response to COVID-19. Partners may submit unsolicited proposals to COVID19_Concepts@usaid.gov.

Department of Homeland Security

Innovative Commercial Products in Support of Coronavirus (COVID-19) Response – Commercial Solutions Opening Pilot Program (CSOP)
Proposals are accepted and considered on a rolling basis until 8/31/2020

  • The Government seeks to rapidly accelerate the testing and fielding of new capabilities, employing innovative commercial products to the detection of exposure, prevention, containment and treatment of COVID-19 and similar microbial threats.

USDA

National Animal Disease Preparedness and Response Program 2020 Cooperative/Interagency Agreements
Applications are due 9/15/20

  • In this funding opportunity, the NADPRP is seeking proposals for projects that will (1) advance capabilities and capacities related to rapid large-scale animal depopulation and carcass disposal in a high-consequence animal disease outbreak, or (2) enhance U.S. livestock biosecurity.

NASA

Making Innovative Use of NASA Satellite Data to Address Environmental, Economic, and/or Societal Impacts of the COVID-19 pandemic
Applications will be accepted on a rolling basis through 3/29/21

  • NASA’s Earth Science Division (ESD) would like to call the attention of the Earth Science research, applications, and data systems communities to Program Element A.28 “Rapid Response and Novel Research in Earth Science” (RRNES) of Research Opportunities in Space and Earth Sciences (ROSES) 2020 as an opportunity to propose investigations making innovative use of NASA satellite data to address regional-to-global environmental, economic, and/or societal impacts of the COVID-19 pandemic.

Non-Federal Opportunities

*NEW* Foundation for Women’s Cancer Diversity and Inclusion Health Equity Research Grant

  • Abstract due 09/21/2020; Full proposal due 11/25/2020
  • Research among diverse populations has demonstrated disparities in treatment outcomes, access to care, genetic testing rates, and disease survival across many diseases. This new Diversity and Health Equity Research Grant is a one-year project where the funding is available for two $75,000 Research grants.
  • The purpose of this award is to support research to understand and eliminate inequities in cancer care, specifically related to differential outcomes experienced by women from underserved or marginalized populations with gynecologic cancer, as well as to increase representation of underrepresented groups in gynecologic oncology as a strategy to achieve health equity for underserved women. Those eligible for applying are those who propose a study focused on a marginalized group, or those who identify as being from an under-represented group within the field of research.
  • This year priority consideration will be given to proposals addressing health disparities in the context of gynecologic cancers related to the COVID-19 pandemic.

*NEW* Johnson & Johnson Nurses Innovate QuickFire Challenge in COVID-19 Patient Care together with the American Organization for Nursing LeadershipTM (AONL) and the Society of Nurse Scientists, Innovators, Entrepreneurs, & Leaders (SONSIEL). Nurses from around the world are invited to submit ideas aiming to improve COVID-19 patient care.

  • Applications close on September 29, 2020
  • We are looking for nurse-led ideas from nurses and nursing students around the world focused on improving COVID-19 patient care, with specific interest in, for example: facilitating remote patient monitoring and communications, data and reporting, resiliency and self-care, supporting a safe return to work or school, supporting sharing of best practices, and addressing racial disparities and inequities in healthcare.
  • Potential nurse-led solutions will be evaluated by a panel of independent nurse reviewers and judges on their ability to meet the following criteria: Potential impact on transforming human health; Uniqueness of the idea; Feasibility of the idea; Thoroughness of approach; Identification of key resources and plan to further idea
  • Areas of interest: Treatment protocols; Health technologies; Medical devices; Treatment pproaches; Consumer products; Community health approaches; Screening tools

Junior Faculty Research Grants for the Study of Lung Cancer and COVID-19 Infection (The LungAmbition Alliance)
Application Portal Closes: 09/15/2020

  • Grant program to support lung cancer research related to Lung Cancer and COVID-19 Infection. The purpose of this program is to fund groundbreaking research related to COVID-19 infected lung cancer patients. The intent of the support is to allow junior faculty researchers, as defined as fewer than 7 years in a faculty position after training, to obtain preliminary data that will enable them to successfully compete for national peer-reviewed grant support.
  • The objective of this program is to support research by new investigators in epidemiology, pathology, imaging, immuno-biology and immune biomarkers, and translational science in COVID-19 positive lung cancer patients. Ultimately, the aim is to improve the quality of care and the outcomes for these patients.
  • The minimum funding for the award will be $50,000. No more than 25% of the requested budget may be used for an Awardee’s salary and/or fringe benefits. No Award budget may be used to fund the purchase of permanent equipment. No indirect costs are provided. Any unused Award funds at the conclusion of the study period will be returned to the study sponsor.

The COVID-19 Symptom Data Challenge

In partnership with Facebook Data for Good, the Delphi Group at Carnegie Mellon University (CMU), the Joint Program on Survey Methodology at the University of Maryland (UMD), the Duke Margolis Center for Health Policy, and Resolve to Save Lives, an initiative of Vital Strategies

Finalist Prizes (1st Place is $50,000; 2nd Place (runner up) is $25,000)

Can you develop a novel analytic approach that uses the CMU/UMD COVID-19 Symptom Survey data to enable earlier detection and improved situational awareness of the outbreak by public health authorities and the general public? Phase I submissions are due by September 29th, 2020 11:59 PM ET

Schmidt Futures The Futures Forum on Learning: Tools Competition
Description: The Futures Forum on Learning: Tools Competition (“Tools Competition”) invites teachers, students, researchers, technologists, and ed tech leaders to propose a tool, technology, platform, or research project that can accelerate recovery from COVID-19-related learning loss for students between grades K-12, and advance the field of learning engineering.

Topics: Solutions should aim to address one of the problem areas:

  • Increase the number of students who are reading by 3rd grade
  • Increase the number of students on track in middle-school math
  • Expand the number of students gaining data and computer science skills in high school
  • Driving more students into college through academic and nonacademic supports
  • Another pressing learning goal identified by the team that is related to COVID-19

Due Dates: One-page concept description due 9/18/2020; detailed proposal due 10/26/2020.

Budget: Applicants will request an award on one of three tracks: $25,000 and under, $25,000-$100,000, and $100,000-$250,000

Wellcome, Bill & Melinda Gates Foundation, and Mastercard
The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The COVID-19 Therapeutics Accelerator will play a catalytic role by accelerating and evaluating new and repurposed drugs and biologics to treat patients with COVID-19 in the immediate term, and other viral pathogens in the longer-term.

Topics: The Accelerator is seeking partners for the following activities:

  • Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
  • Developing drugs or monoclonal antibodies that pass initial screening.
  • Scaling up production and commercialization of successful drugs and monoclonal antibodies.

March of Dimes 2020 COVID-19 Fund
Applications are due 9/4/20

  • Supports (1) studies that examine clinical and socio-demographic predictors of perinatal health outcomes and treatments associated with COVID-19 for the mom-baby dyad and (2) studies examining the role of antibody testing in birth planning and postpartum care, sustainability of antibodies/immunity in mom-baby dyad, the viability of passive immunity through breastmilk, and mom-to-baby contact.

State and Community-Based COVID-19 Testing (bid number ERFQ30034902100092) 
Applications are due 8/5/2020

PCORI Phased Large Awards in Comparative Effectiveness Research (PLACER)
LOI applications are due 9/29/2020. Full applications are due 1/12/2021.

  • This PCORI funding announcement invites applications for high-quality comparative effectiveness research (CER) projects that will examine a critical patient-centered research question that is also relevant to decision makers and other stakeholders. For this PFA, investigators should propose an individual-level or cluster randomized controlled trial of significant scale and scope, requiring funding in excess of $10 million in direct costs. The proposed trials should address important decisional dilemmas that require important new evidence about the comparative effectiveness of available interventions.

CISCO Pandemic/COVID19 Science, Technology and Social Impact

  • Cisco is interested in both the science and technology aspects of these problem sets, and, particularly, in the intersections between them. By cultivating stronger partnerships between scientists, technologists, and the broader community; we hope to achieve an acceleration of scientific research and conservation outcomes as we push the boundaries of our technologies and architectures to support larger-scale studies, more sophisticated analyses, and translation of learnings across multiple domain areas.

COVID-19 Early Treatment Fund (CETF)
Applications are accepted on a rolling basis

  • CETF is raising funds to test the most promising existing drugs in outpatient trials and helping those studies recruit patients. We are the only organization in the world that is exclusively focused on outpatient trials testing treatments immediately after infection. A scientist can apply for funding and get up to a $1M commitment in less than a week. Funding multiple shots on goal quickly is the fastest way to end the pandemic.

Robert Wood Johnson Foundation (RWJF): Pioneering Ideas – Exploring the Future to Build a Culture of Health
Proposals will be accepted on a rolling basis throughout the year

  • Pioneering Ideas: Exploring the Future to Build a Culture of Health seeks proposals that are primed to influence health equity in the future. The Foundation is interested in ideas that address any of these four areas of focus: Future of Evidence; Future of Social Interaction; Future of Food; Future of Work. RWJF welcomes proposals from scientists, anthropologists, artists, urban planners, and community leaders – anyone, anywhere who has a cutting edge idea that could alter the trajectory of health and increase opportunities for everyone in the United States to live their healthiest life possible.
  • While this RFP is focused on broader and longer-term societal trends and shifts that were evolving prior to the COVID-19 outbreak, the Foundation recognizes the unique circumstances and learning created by the COVID-19 pandemic may inform your response. It is at your discretion whether you propose a project related to the pandemic directly or indirectly.

Mozilla – Mozilla Open Source Support Program (MOSS) COVID-19 Solutions Fund
Applications are accepted on a rolling basis

  • Mozilla will provide awards of up to $50,000 each to open source technology projects which are responding to the COVID-19 pandemic in some way. As part of the COVID-19 Solutions Fund, we will accept applications that are hardware (e.g., an open source ventilator), software (e.g., a platform that connects hospitals with people who have 3D printers who can print parts for that open source ventilator), as well as software that solves for secondary effects of COVID-19 (e.g., a browser plugin that combats COVID related misinformation).

FastGrants – Fast Funding for COVID-19 Science
Applications accepted on a rolling basis – current on hold due to large number of application received.

  • Science funding mechanisms are too slow in normal times and may be much too slow during the COVID-19 pandemic. Fast Grants are an effort to correct this. If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. If we approve the grant, you’ll receive payment as quickly as your university can receive it

PCORI Funding Opportunity for COVID-19-Related Enhancements to Existing PCORI-Funded Research
Applications accepted on a rolling basis

  • PCORI seeks investigator-initiated proposals to address the COVID-19 public health crisis through enhancements of currently funded PCORI research awards. Only PCORI-funded principal investigators with active research project funding contracts are eligible to submit a proposal in response to this announcement.

Merck Research Grants for Pandemic Preparedness
Submissions will be accepted until 31 August 2020 23:59 CEST

  • Merck is offering a grant comprising up to 250,000 €/year for 3 years with the option of extension. Proposals will be considered that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections. 

Wellcome Trust – Epidemic Preparedness: COVID-19 Funding Call
Applications accepted on rolling basis

  • Applicants must be able to swiftly begin to investigate new approaches for preventing and controlling COVID-19. Proposals should focus on helping low- and middle-income countries prepare for and deal with the epidemic. Eligible applicants are researchers with a PhD or the equivalent, and significant postdoctoral research experience. These awards are open to individuals or teams of up to five members. Applicants can be based anywhere in the world (apart from mainland China). Wellcome Trust particularly encourages applications from lead applicants based in low- and middle-income countries.

Relevant Links

Additional COVID-19 Funding Opportunities

SPIN COVID-19 Links

Webinar: Proposal Writing in the Time of COVID-19 Recording and Slides from June 11, 2020

*NEW* Institute for Public Health Annual Conference: COVID-19 Pandemic Response, Lessons Learned and Recovery

  • Virtual poster session on 10/28/2020 and the Conference, a hybrid event on 10/29/2020